Goldenwell Biotech (GWLL) Net Cash Flow (2019 - 2025)
Goldenwell Biotech (GWLL) has disclosed Net Cash Flow for 7 consecutive years, with -$30885.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Net Cash Flow fell 63.72% year-over-year to -$30885.0, compared with a TTM value of $40868.0 through Sep 2025, up 1478.81%, and an annual FY2024 reading of -$3827.0, down 152.9% over the prior year.
- Net Cash Flow was -$30885.0 for Q3 2025 at Goldenwell Biotech, down from $59381.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $157619.0 in Q3 2021 and bottomed at -$917090.0 in Q4 2022.
- Average Net Cash Flow over 5 years is -$48395.0, with a median of -$18865.0 recorded in 2024.
- The sharpest move saw Net Cash Flow soared 18052.05% in 2021, then crashed 4633.86% in 2022.
- Year by year, Net Cash Flow stood at -$19373.0 in 2021, then plummeted by 4633.86% to -$917090.0 in 2022, then soared by 104.5% to $41312.0 in 2023, then increased by 8.08% to $44649.0 in 2024, then crashed by 169.17% to -$30885.0 in 2025.
- Business Quant data shows Net Cash Flow for GWLL at -$30885.0 in Q3 2025, $59381.0 in Q2 2025, and -$32277.0 in Q1 2025.